Rocuronium 1.5mg/kg/hr for Prostate Cancer

Phase-Based Estimates
Memorial Sloan Kettering Cancer Center, New York, NY
Prostate Cancer+1 More
Rocuronium 1.5mg/kg/hr - Drug
Eligible conditions
Prostate Cancer

Study Summary

This study is evaluating whether the amount of pressure used during surgery may impact post-surgery pain.

See full description

Eligible Conditions

  • Prostate Cancer
  • Prostatic Neoplasms

Treatment Effectiveness

Effectiveness Estimate

1 of 3

Study Objectives

This trial is evaluating whether Rocuronium 1.5mg/kg/hr will improve 2 primary outcomes in patients with Prostate Cancer. Measurement will happen over the course of 1 year.

1 year
Difference in levels of Intra-Abdominal Pressure (IAP) when performing robotic prostatectomy in participants under a moderate vs deep Neuromuscular Blockade technique
Difference in levels of postoperative pain in participants under a moderate vs deep Neuromuscular Blockade technique during robotic prostatectomy using the Visual Analog Scale (VAS)

Trial Safety

Safety Estimate

2 of 3
This is better than 68% of similar trials

Trial Design

2 Treatment Groups

Control Group: Moderate Neuromuscular Blockade
Interventional Group: Deep Neuromuscular Blockade

This trial requires 130 total participants across 2 different treatment groups

This trial involves 2 different treatments. Rocuronium 1.5mg/kg/hr is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.

Interventional Group: Deep Neuromuscular Blockade
The Deep NMB group (Intervention) will have rocuronium infusion titrated to deep paralysis defined as PTC of 1-2 (infusion start rate 0.025mg/kg/min or 1.5mg/kg/hr).
Control Group: Moderate Neuromuscular Blockade
The Moderate NMB group (Control ) will have rocuronium infusion titrated to moderate paralysis defined as TOF of 1-2 (infusion start rate 0.005mg/kg/min or 0.3mg/kg/hr).

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 1 year
This trial has the following approximate timeline: 3 weeks for initial screening, variable treatment timelines, and roughly 1 year for reporting.

Closest Location

Memorial Sloan Kettering Cancer Center - New York, NY

Eligibility Criteria

This trial is for male patients aged 18 and older. There are 4 eligibility criteria to participate in this trial as listed below.

Mark “yes” if the following statements are true for you:
Adult patients under the age of 80
American Society of Anesthesiologists Physical Status 1, 2, 3.
Elective Robotic Prostatectomy
Patient undergoing surgery at Josie Robertson Surgical Center

Patient Q&A Section

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are the signs of prostate cancer?

Add answer

Symptoms of prostate cancer are usually gradual. Symptoms frequently precede the development of a symptomatic tumour by one to two years. Symptoms usually include an inability to urinate or to pass urine at night. Symptoms may also include weakness and trouble with ejaculation. Some men also have problems with incontinence. Symptoms also may include increased fat in the bones of the back, a lump in the testes or lumps in the neck. Complications of prostate cancer include low libido and impotence. Complications are more likely to occur in men who have had prostate cancer before.

Unverified Answer

How many people get prostate cancer a year in the United States?

Add answer

The incidence of PCa in the United States is increasing as previously observed in other developing countries. The age-standardized incidence rates of PCa incidence rates are 3.5-4.0/100,000 population per year for whites, and 4-4.5/100,000 population per year for black and gray and Hispanics. In the next 3-4 decades, it is projected that approximately 2.5 million persons in the United States will develop PCa, including a new population of PCa survivors who are at a higher risk of PCa recurrence.

Unverified Answer

What is prostate cancer?

Add answer

The 5-year and 10-year disease-specific survival rates were 73% and 66%, respectively, with a median survival of 80+ months. The 5-year and 10-year disease-specific mortality rates were 25% and 24%, respectively. Median survival time was 77+ months. Results from a recent clinical trial, the 10-year disease-specific survival rate was comparable to that described in the literature but shorter than those quoted in studies of other countries. Most treatments are conservative, and the mortality and morbidity are significantly increased in men with high-risk disease, especially with metastatic disease.

Unverified Answer

Can prostate cancer be cured?

Add answer

Prostate cancer has not been found to be cured, but can be controlled with treatment. Prostate cancer often begins as a slow-growing (stage T1 or T2) or asymptomatic (prostate-specific antigen undetectable disease) prostate tumor. Prostate cancer can be cured if all the cancer is removed. The cure rate depends on the stage of the cancer when treatment is started. For Stage T1 cancer, 80% can be cured with radical prostatectomy; with Stage T2 or T3 disease, 75% to 90% can be cured, and with Stage 4 disease, 25% to 40% can be cured. Prostate cancer is the second deadliest cancer in the U.S.

Unverified Answer

What are common treatments for prostate cancer?

Add answer

Patients younger than seventy-five must be aware of the risks of radiation therapy and have an opportunity for counseling regarding the risks and benefits of the therapy.

Unverified Answer

What causes prostate cancer?

Add answer

The most famous cause of prostate cancer is age, and other factors such as gender, race and alcohol intake are known to be inversely associated. Furthermore, it is clear that other environmental risks must be involved as well, but the reason why these other risks are not causative is not clear. Finally, there is some evidence that prostate cancer has a genetic component. Prostate cancer, thus, may be a disease of multiple causes.

Unverified Answer

Who should consider clinical trials for prostate cancer?

Add answer

Patients with high baseline risk PSA levels, low-volume intermediate- and high-risk disease and high-risk Gleason scores will be interested in joining treatment trials. Patients with favorable-risk disease and low-volume intermediate- and high-risk disease would not be eligible.

Unverified Answer

What does rocuronium 1.5mg/kg/hr usually treat?

Add answer

We think, that rocuronium 1.5 mg/kg/hr should be used when the patient has an increased response to the stimuli of muscle contraction during surgery, for the avoidance of the occurrence of muscle relaxant.

Unverified Answer

Does rocuronium 1.5mg/kg/hr improve quality of life for those with prostate cancer?

Add answer

Rocuronium 1.5 mg/kg/hr in all patients with [prostate cancer]( undergoing transrectal ultrasound guided needle-core prostate biopsy resulted in significantly shorter mean biopsy time but no difference in mean duration of anaesthesia, or postoperative analgesic requirements.

Unverified Answer

What is rocuronium 1.5mg/kg/hr?

Add answer

Rocuronium 1.5 mg/kg/hr is a safe and reliable way to intubate patients receiving spinal anaesthesia. This technique was similar to that described in this series of two cases, and was not influenced by the body weight or the sex of the patient.

Unverified Answer

What is the average age someone gets prostate cancer?

Add answer

There appears to be no statistically significant age at diagnosis disparity in [prostate cancer](, at least in the US. Possible factors in these data include the more frequent use of the prostate-specific antigen test in men, a higher frequency of early detection, and different screening schedules with later onset of disease.

Unverified Answer

What is the latest research for prostate cancer?

Add answer

The major goals of PC research should include improved therapies (in particular for metastatic PC), reduced chemotherapy-related morbidity in elderly patients, better patient selection for radiation therapy, and reduction of PC mortality.

Unverified Answer
See if you qualify for this trial
Get access to this novel treatment for Prostate Cancer by sharing your contact details with the study coordinator.